INTI · Inhibitor Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $0 | $0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $1.70M | $1.68M | $1.38M | $6.2K | $4.9K | $185.3K |
| SG&A | $1.73M | $1.97M | $2.02M | $651.8K | $320.5K | $873.7K |
| Total Operating Expenses | $3.43M | $3.66M | $3.40M | $657.9K | $325.4K | $1.06M |
| D&A | - | - | - | - | - | - |
| Operating Income | ($3.43M) | ($3.66M) | ($3.40M) | ($657.9K) | ($325.4K) | ($1.06M) |
| Interest Expense | - | - | - | $14.8K | - | - |
| Income Tax | - | - | - | $55.1K | $0 | $0 |
| Net Income | ($3.30M) | ($3.34M) | ($3.03M) | $12.11M | ($298.6K) | ($1.06M) |
| EPS - Basic | ($0.02) | ($0.02) | ($0.02) | $0.00 | - | - |
| EPS - Diluted | ($0.02) | ($0.02) | ($0.02) | $0.00 | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.38M | $5.61M | $8.84M | $11.95M | $30.6K | $75.1K |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $51.5K | $15.9K | $33.7K | $145.2K | $279.8K | $269.4K |
| Current Assets | $2.45M | $5.69M | $8.95M | $11.98M | $58.8K | $107.4K |
| Total Assets | $2.51M | $5.69M | $8.95M | $11.98M | $58.8K | $131.8K |
| Current Liabilities | $766.3K | $709.6K | $665.2K | $678.8K | $679.6K | $425.4K |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $3.80M | $3.71M | $3.67M | $3.68M | $3.68M | $3.49M |
| Stockholders' Equity | ($1.29M) | $1.99M | $5.28M | $8.30M | ($3.62M) | ($3.36M) |
| Retained Earnings | ($55.42M) | ($52.12M) | ($48.78M) | ($45.75M) | ($57.67M) | ($57.17M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.23M) | ($3.23M) | ($2.70M) | $11.74M | ($220.4K) | ($825.4K) |
| Investing Cash Flow | - | - | - | - | - | - |
| Financing Cash Flow | - | - | ($411.0K) | $180.0K | $176.0K | $96.6K |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | 0.5% | - | - |
| Return on assets | -131.4% | -58.6% | -33.8% | 101.1% | -508.0% | -802.9% |
| Return on equity | 255.5% | -168.2% | -57.3% | 145.9% | 8.2% | 31.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.19 | 8.02 | 13.45 | 17.64 | 0.09 | 0.25 |
| Quick ratio | 3.19 | 8.02 | 13.45 | 17.64 | 0.09 | 0.25 |
| Cash ratio | 3.10 | 7.90 | 13.29 | 17.61 | 0.05 | 0.18 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | -44.3x | - | - |
| Equity multiplier | -1.94 | 2.87 | 1.69 | 1.44 | -0.02 | -0.04 |
| Liabilities / Assets | 1.51 | 0.65 | 0.41 | 0.31 | 62.60 | 26.50 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 6.3% | -7.4% | -417.5% | -102.2% | 69.3% | 61.5% |
| Net income growth (YoY) | 1.2% | -10.3% | - | - | 71.8% | 61.3% |
| EPS growth (YoY) | 0.0% | 0.0% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -62.4% | -36.3% | - | -7.8% | -32.8% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Inhibitor Therapeutics against the 5 most active filers in the same SIC group.